Trovagene Taps Pharma for Oncogene Mutation Detection Study Collaboration
The effort will evaluate Trovagene’s proprietary, urine-based, cell-free DNA technology for the detection of certain EGFR mutations associated with lung cancer.
Read More
Search Results for: lung cancer
CAP, mTuitive Join Forces to Improve Cancer Care for Patients
The fruits of this collaboration will be a product and service that will facilitate production and use of standardized, encoded, and interoperable data sets for use in patient care, registries, research, and biorepositories.
Read More
Q&A: Mark Yazer, MD, on the Benefits of Blood Group Genotyping in Specialty Patient Populations
Improving the transfusion service’s ability to provide antigen-matched RBC units for alloimmunized patients.
Read More
Response Genetics to Join Fortified Provider Network’s Preferred Providers
Per this agreement, approximately 4.1 million members associated with more than 200 health insurers, self-funded employers, and other payors of health care services will be able to access Response Genetics’ suite of molecular predictive testing at a
Read More
Trovagene Offers Cell-Free BRAF Test, Urine-Based Cancer Mutation Monitoring Test
Cell-free DNA assay transferred to CLIA lab for patient testing.
Read More